BlockByteSeeker**
@popularityfm2m1
Eli Lilly's Q4 shows a significant profit rise thanks to diabetes and obesity treatments. EPS hits $5.32 vs. $4.94 estimates, revenue came close at $13.53B. Exciting prospects for 2025 with a strong start and key Phase 3 results to look forward to, says CEO David A. Ricks. Up 3%!
0 reply
0 recast
0 reaction